Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTS-29: Neoadjuvant Chemoradiotherapy + Pembrolizumab for ESCC
NCT02844075Phase 2Completed
- Sponsor
- Yonsei University
- Start
- Jan 2017
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Yonsei University. Started Jan 2017; status: completed.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02844075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02844075.